Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα / β1 during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours. in vitro

Severe Acute Respiratory Syndrome

Ventilation Pneumonitis

Ivermectin 5 MG/ML

Hospital Eurnekian

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

Considering healing and/or reducing symptoms and severity of initial presentation

Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

potential need of reducing or augmenting doses

Outcome of adverse effects to one or more drugs used in the clinical trial

Personal data will remain secret. Only clinical descriptions (age, gender, co-morbidities, evolution, outcomes will be released

Hector E Carvallo

Principal investigator

Eurnekian Public Hospital

patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)

patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo

Aneurysm Abdominal

Endovacular Repair

naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair

Drugs, Generic (Naprosyn)

placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair

Placebo Oral Tablet

University of Thessaly

Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing EVAR for AAA

Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing Endovascular Repair of an Abdominal Aortic Aneurysm Under General Anesthesia

The occurrence of major cardiovascular event (myocardial infarction, stroke, transient ischemic attacks, cardiac arrythmia, congestive heart failure, angina unstable, cardiac death) after EVAR

the occurence of postimplantation syndrome after EVAR

Elena Arnaoutoglou

Professor of Anesthesiology

Ovarian Cancer Prevention

Acetylsalicylic acid

Placebo

Prince of Wales Hospital

Westmead Hospital

Peter McCallum Cancer Institute

St John of God Subiaco

Tom Baker Cancer Centre

Clinical Research Unit at Vancouver Coastal

CancerCare Manitoba

Dr. H. Bliss Murphy Cancer Centre

Kingston Health Sciences Centre

North York General Hospital

Women's College Hospital

CIUSSS de l'Est-de-I'lle-de-Montreal

CHUM-Centre Hospitalier de l'Universite de Montreal

The Jewish General Hospital

Hotel-Dieu de Quebec

CIUSSS de l'Estrie - Centre hospitalier

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)

Canadian Cancer Trials Group

Apotex Inc.

Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.

BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.

Polycythemia Vera (PV)

Essential Thrombocythemia (ET)

Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.

Ruxolitinib

BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).

Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie

Universitätsklinikum Ulm Klinik für Innere Medizin III

Rems-Murr Klinikum Winnenden

Studienzentrum Aschaffenburg

III. Medizinischen Klinik des Klinikums rechts der Isar der TU München

Klinikum Nürnberg Nord Medizinische Klinik 5

Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik

Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III

Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik

Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie

Universitätsklinikum Essen Klinik für Hämatologie

Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin

Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie

Marienhospital

Zentrum für ambulante Hämatologie und Onkologie (ZAHO)

Uniklinik RWTH Aachen

InVO - Institut für Versorgungsforschung in der Onkologie

Universitätsklinikum Magdeburg

Universitätsklinikum Halle (Saale)

Klinikum Chemnitz gGmbH Klinik für Innere Medizin III

Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I

Charité Universitätsmedizin Berlin Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie

Universitätsklinikum Freiburg - Klinik für Innere Medizin I

Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie

Universitätsklinik Jena - Klinik für Innere Medizin II

Universitätsklinikum Leipzig - Medizinische Klinik und Poliklinik I

UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009

acetylsalicylic acid/fiabhras

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing EVAR for AAA

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht